Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifostine with Chemoradiation for Head and Neck Cancer
NCT00095927Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2003
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of amifostine in xerostomia (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Rate of local/regional control at 1 year, Proportion of patients with grade 2 or 3 chronic xerostomia at 6 months and 2 more. Started May 2003; status: completed.
02
Drugs
amifostine
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT00095927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095927.